Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.

Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A.

PLoS One. 2012;7(3):e31866. doi: 10.1371/journal.pone.0031866. Epub 2012 Mar 9. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/c4cb1c2c-a436-4f7a-ada9-1feb42aebca1.


Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H.

PLoS Med. 2006 Nov;3(11):e427.


A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier.

McFarren A, Lopez L, Williams DW, Veenstra M, Bryan RA, Goldsmith A, Morgenstern A, Bruchertseifer F, Zolla-Pazner S, Gorny MK, Eugenin EA, Berman JW, Dadachova E.

AIDS. 2016 Feb 20;30(4):563-72. doi: 10.1097/QAD.0000000000000968.


Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF.

J Virol. 2008 Jan;82(1):115-25. Epub 2007 Oct 17.


Properties of anti-gp41 core structure antibodies, which compete with sera of HIV-1-infected patients.

Usami O, Xiao P, Ling H, Liu Y, Nakasone T, Hattori T.

Microbes Infect. 2005 Apr;7(4):650-7. Epub 2005 Mar 17.


Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S.

J Virol. 2000 Aug;74(15):7096-107.


Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.


Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.

Curriu M, Fausther-Bovendo H, Pernas M, Massanella M, Carrillo J, Cabrera C, López-Galíndez C, Clotet B, Debré P, Vieillard V, Blanco J.

PLoS One. 2012;7(2):e30330. doi: 10.1371/journal.pone.0030330. Epub 2012 Feb 1.


Competitive study of monoclonal antibodies against the HIV-1 Gp41 core structure.

Usami O, Xiao P, Ling H, Hattori T.

Microbiol Immunol. 2006;50(2):131-4.


In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.


HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.


Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice.

Sanhadji K, Grave L, Touraine JL, Leissner P, Rouzioux C, Firouzi R, Kehrli L, Tardy JC, Mehtali M.

AIDS. 2000 Dec 22;14(18):2813-22.


In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.

Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, Olson WC.

J Immunol. 2003 Feb 15;170(4):2236-41.


A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.

Cotropia J, Ugen KE, Kliks S, Broliden K, Broliden PA, Hoxie JA, Srikantan V, Williams WV, Weiner DB.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):221-32.


Supplemental Content

Support Center